MCC950 Sodium: Selective NLRP3 Inflammasome Inhibition in Inflammatory Disease Models

Executive Summary: MCC950 sodium (also known as CRID3 sodium salt) is a potent, selective inhibitor of the NLRP3 inflammasome with an IC₅₀ of 7.5 nM in murine macrophages, showing comparable efficacy in human cells (APExBIO, B7946). It blocks both canonical and noncanonical NLRP3 activation without affecting AIM2, NLRC4, or NLRP1 inflammasomes (Yuan et al., 2022). MCC950 sodium demonstrates high solubility in water (≥124 mg/mL), DMSO, and ethanol, and is stable at −20°C when stored dry. In vivo, it reduces serum IL-1β/IL-6 levels and disease severity in autoimmune encephalomyelitis models. The compound is essential for research on NLRP3-driven inflammatory and autoimmune diseases, providing mechanistic clarity and translational value.

Biological Rationale

The NLRP3 inflammasome is a multiprotein complex that senses pathogen- and damage-associated molecular patterns. Its activation leads to caspase-1–dependent maturation of IL-1β and IL-18, driving inflammatory responses and pyroptotic cell death (Yuan et al., 2022). Dysregulated NLRP3 activity is implicated in atherosclerosis, autoimmune disorders, and neuroinflammation. Endothelial dysfunction and macrophage pyroptosis, both linked to NLRP3 activation, are early events in atherosclerotic lesion development and broader inflammatory pathologies (Yuan et al., 2022).

Selective chemical inhibition of NLRP3, as achieved with MCC950 sodium, enables precise interrogation of this signaling pathway in disease models. This approach distinguishes NLRP3-dependent inflammation from other inflammasome-mediated and cytokine-driven processes, supporting drug development and basic research. For a strategic and mechanistic view of NLRP3 targeting, see this translational strategy review; this article extends that resource by systematically detailing MCC950 sodium’s evidence base and workflow integration.

Mechanism of Action of MCC950 sodium

MCC950 sodium directly inhibits NLRP3 by binding to its NACHT domain, preventing ATP hydrolysis and subsequent inflammasome assembly (APExBIO, B7946). This blocks caspase-1 activation and the maturation of IL-1β and IL-18. Importantly, MCC950 sodium does not inhibit structurally similar inflammasomes such as AIM2, NLRC4, or NLRP1, ensuring pathway specificity (Yuan et al., 2022). In cell-based assays, MCC950 sodium inhibits IL-1β release dose-dependently in both murine and human macrophages, without affecting TNF-α secretion. This specificity provides a critical advantage for dissecting NLRP3-dependent mechanisms from general cytokine responses.

MCC950 sodium blocks both canonical (e.g., triggered by LPS/ATP) and noncanonical (e.g., triggered by intracellular LPS or oxidants) activation routes of NLRP3. In the context of endothelial cell injury, MCC950 sodium suppresses H₂O₂-induced pyroptosis, confirming its action downstream of diverse stress signals (Yuan et al., 2022).

Evidence & Benchmarks

• MCC950 sodium inhibits NLRP3 inflammasome activation in murine bone marrow–derived macrophages (BMDMs) with an IC₅₀ of 7.5 nM (APExBIO, product page).
• Comparable nanomolar potency and selectivity are observed in human monocyte-derived macrophages (HMDMs) (APExBIO).
• In cell models, MCC950 sodium blocks both canonical and noncanonical NLRP3 activation but does not affect AIM2, NLRC4, or NLRP1 inflammasomes (Yuan et al., 2022).
• In human umbilical vein endothelial cells (HUVECs), MCC950 sodium (10 μM, 2 h) suppresses H₂O₂-induced pyroptosis and preserves cell viability (Yuan et al., 2022).
• In animal models, MCC950 sodium reduces serum IL-1β and IL-6 levels and attenuates disease severity in experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis (APExBIO).
• MCC950 sodium is highly soluble with ≥124 mg/mL in water, ≥21.45 mg/mL in DMSO, and ≥43 mg/mL in ethanol (APExBIO, product page).
• For a mechanistic discussion and competitive landscape overview, this article surveys recent endothelial and translational studies; the present article provides more granular benchmarks and application parameters.

Applications, Limits & Misconceptions

MCC950 sodium is a critical reagent for dissecting NLRP3-dependent inflammatory signaling in vitro and in vivo. It is widely applied in models of atherosclerosis, neuroinflammation, and autoimmune diseases, including EAE. Its selectivity allows for precise attribution of phenotypes to NLRP3 activity, facilitating therapeutic target validation and biomarker discovery. For an overview of MCC950 sodium in model systems, see this article; the current review updates with new evidence and workflow guidance.

Common Pitfalls or Misconceptions

• MCC950 sodium does not inhibit non-NLRP3 inflammasomes (e.g., AIM2, NLRC4, NLRP1); negative results in these pathways should not be interpreted as lack of inflammasome inhibition (Yuan et al., 2022).
• It does not directly block TNF-α or non-inflammasome cytokine release; effects observed on these markers may reflect downstream network changes, not direct inhibition (APExBIO).
• Stability is compromised by long-term storage in solution; stock solutions should be prepared fresh or stored at −20°C for limited periods (APExBIO).
• Results may not extrapolate to species or cell types lacking functional NLRP3; verify NLRP3 expression in new models.
• Not a therapeutic drug: MCC950 sodium is for research use only and not approved for human use.

Workflow Integration & Parameters

Solubility and Preparation: MCC950 sodium is water-soluble (≥124 mg/mL) and compatible with DMSO and ethanol. Solutions should be prepared fresh, filtered, and stored at −20°C if not used immediately (APExBIO).

Cellular Assays: Dosing in the 1–10 μM range is typical for macrophages and endothelial cells; 2 h pre-treatment is effective in HUVEC pyroptosis models (Yuan et al., 2022).

Animal Studies: Intraperitoneal administration is standard; dosing regimens should be tailored to disease model and readout. Serum cytokine analysis (IL-1β, IL-6) is a common efficacy metric.

Controls: Include positive (e.g., VX-765) and negative controls (vehicle, untreated) to validate inflammasome specificity. Confirm NLRP3 expression in all test systems.

Conclusion & Outlook

MCC950 sodium (B7946) is the gold standard for selective NLRP3 inflammasome inhibition in preclinical research. Its nanomolar potency, pathway specificity, and robust solubility make it indispensable for studies of inflammatory and autoimmune disease mechanisms. Ongoing research is expanding its utility in diverse disease models and translational frameworks. For detailed protocols and ordering, see the MCC950 sodium product page.